Health care costs in US patients with and without a diagnosis of osteoarthritis by Le, T Kim et al.
© 2012 Le et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Pain Research 2012:5 23–30
Journal of Pain Research
Health care costs in US patients with and  
without a diagnosis of osteoarthritis
T Kim Le1
Leslie B Montejano2
Zhun Cao2
Yang Zhao1
Dennis Ang3
1Eli Lilly and Company, Indianapolis, 
IN, 2Thomson Reuters, Washington, 
DC, 3Indiana University School of 
Medicine, Indianapolis, IN, USA
Correspondence: Leslie Montejano 
4301 Connecticut Avenue, NW, Suite 330, 
Washington, DC 20008, USA 
Tel +1 202 719 7800 
Fax +1 202 719 7801 
Email leslie.montejano@thomsonreuters.
com
Background: Osteoarthritis is a chronic and costly condition affecting 14% of adults in the 
US, and has a significant impact on patient quality of life. This retrospective cohort study 
compared direct health care utilization and costs between patients with osteoarthritis and a 
matched control group without osteoarthritis.
Methods: MarketScan® databases were used to identify adult patients with an osteoarthritis 
claim (ICD-9-CM, 715.xx) in 2007, and the date of first diagnosis served as the index. Patients 
were excluded if they did not have 12 months of continuous health care benefit prior to and 
following the index date, were aged ,18 years, or lacked a second diagnosis code for 
osteoarthritis between 15 and 365 days pre-index or post-index. Osteoarthritis patients were 
matched 1:1 to patients without osteoarthritis for age group, gender, geographic region, health 
plan type, and Medicare eligibility. Multivariate analyses were conducted to assess for differ-
ences in utilization and costs, controlling for differences between cohorts.
Results: The study sample included 258,237 patients with osteoarthritis and 258,237 matched 
controls without osteoarthritis. Most patients were women and over 55 years of age. Patients 
with osteoarthritis had significantly higher pre-index rates of comorbidity than controls. Mean 
total adjusted direct costs for osteoarthritis patients were more than double those for the control 
group at US$18,435 (95% confidence interval [CI]: US$18,318–US$18,560) versus US$7494 
(95% CI: US$7425–US$7557). Osteoarthritis patients incurred significantly higher inpatient 
costs at US$6668 (95% CI: US$6587–US$6744) versus US$1756 (95% CI: US$1717–
US$1794), outpatient costs at US$7840 (95% CI: US$7786–US$7902) versus US$3675 (95% 
CI: US$3637–US$3711), and prescription drug costs at US$3213 (95% CI: US$3195–US$3233) 
versus US$2245 (95% CI: US$2229–US$2262) compared with the controls.
Conclusion: The direct health care costs of osteoarthritis patients were over two times higher 
than those of similar patients without the condition. The primary drivers of the cost difference 
were comorbidities and inpatient costs.
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Introduction
Osteoarthritis is a debilitating joint disease characterized by joint pain, joint inflam-
mation, stiffness, and functional disability.1 It is estimated that approximately 14% of 
US adults are affected by osteoarthritis, and of these, 33.6% are aged 65 years or older.2 
The prevalence of osteoarthritis is rapidly increasing, and this is likely a result of the 
aging population and an increase in the prevalence of obesity.1,3 During the decade 
from 1995 to 2005, the number of Americans with osteoarthritis increased from about 
21 million to 27 million.4
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Osteoarthritis is a leading cause of disability among US 
adults, and has a significant and negative impact on quality 
of life, with many patients experiencing fatigue, decreased 
sleep quality, reduced mental health, social function, and 
work productivity.5 Additionally, rates of comorbidities are 
high among this population, with depression, hypertension, 
cardiovascular disease, respiratory disease, diabetes, and 
renal disease being the most frequently reported conditions.1 
These conditions together with osteoarthritis further impair 
patient quality of life.
The economic burden associated with osteoarthritis is 
substantial. White et al calculated the average total direct 
medical costs for adults with osteoarthritis in 2005 US cur-
rency to be $11,542.1 Using nationally representative survey 
data, it was estimated that, in the presence of osteoarthritis, 
predicted annual insurer and patient out-of-pocket costs 
increased by US$4833 and US$1379 for women, respectively, 
and by US$4036 and US$694 for men,   respectively.6 In 
another retrospective analysis of a large insurance claims 
database by Dunn and Pill, the mean charge per patient per 
year for osteoarthritis-related services was $5938 in 2007 
US currency.7
With the increasing prevalence of osteoarthritis and 
increasing costs of health care, it is important to understand 
the health care utilization and costs associated with this 
condition. Although a handful of studies detailing the cost 
of illness of osteoarthritis in the US has been published, the 
majority of these studies utilized data from the 1990s or data 
from a single health plan, which limits the generalizability 
of the results.6,8 Few recent studies assessing the economic 
burden of this common condition have been conducted,9 none 
of which compared costs incurred by osteoarthritis patients 
with controls.
The main objective of the current study was to compare 
the direct health care costs of osteoarthritis in affected patients 
and matched controls to determine the health care resource 
utilization and cost burden associated with osteoarthritis using 
a US research database. A secondary objective was to identify 
the drivers of cost in patients with osteoarthritis.
Materials and methods
Deidentified health insurance claims from January 1, 2006 
to December 31, 2009, drawn from the Thomson Reuters 
MarketScan® Commercial and Medicare Supplemental 
Databases were used retrospectively to analyze the direct 
health care costs of patients with osteoarthritis and matched 
controls without osteoarthritis. The MarketScan databases 
are compiled from insurance claims of individuals with health 
care coverage provided by over 100 employer-sponsored and 
private health plans located throughout the US. Data from 
employees and their dependants are contained in the 
  MarketScan Commercial Database, while the MarketScan 
Medicare Supplemental Database contains data from 
Medicare beneficiaries with comprehensive employer-
sponsored supplemental coverage. The databases include 
fully adjudicated claims that provide detailed utilization and 
cost information from inpatient and outpatient settings, 
including retail and mail order pharmacies. The MarketScan 
Medicare Database is limited to plans where both the 
Medicare-paid and employer-paid amounts are available to 
help ensure that patient claim histories are complete.
The osteoarthritis cohort was selected from patients with 
an osteoarthritis diagnosis (ICD-9-CM, 715.xx) on an inpa-
tient or outpatient claim in 2007, with the date of first diag-
nosis as the index date. To ensure sample specificity, at least 
one additional osteoarthritis diagnosis on or between 15 and 
365 days pre-index or post-index was required. A shorter 
timeframe for the confirmatory diagnosis may have errone-
ously included rule-out diagnoses as evidence of the disease; 
a longer timeframe was not possible given the pre- and post-
periods employed in the study. Laboratory and radiology 
claims were not used to identify the study sample because 
they may carry rule-out diagnoses. Patients without continu-
ous enrollment with medical, prescription drug, and mental 
health coverage over the 12 months pre- and post-index 
periods, or patients younger than 18 years as of the index 
date were excluded. The remaining patients comprised the 
osteoarthritis cohort.
Osteoarthritis patients were matched 1:1 to controls 
without osteoarthritis. A power analysis determined a 
1:1 match ratio would detect a minimal ($2%) difference in 
total costs between cohorts with a power of 92%. Power of 
90%–95% is a reasonable goal in most research contexts.10 
Controls were selected from adults with no osteoarthritis 
claims in 2006 through 2008 and at least 24 months of con-
tinuous enrollment with medical, prescription drug, and 
mental health coverage over the study period. Controls were 
directly matched to osteoarthritis patients on age group, 
gender, geographic region, health plan type, and Medicare 
eligibility. Index dates were assigned to controls based on 
the index date distribution for osteoarthritis patients.
Patient demographics and clinical characteristics were 
identified from the database. Demographic variables were 
defined as of the index date, and included age, gender, geo-
graphic region, and health plan characteristics. The Deyo 
adaptation of the Charlson Comorbidity Index (CCI)11 was 
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calculated in the 12 month pre-index period. A CCI score of 
zero suggests a patient has no or minimal comorbid burden, 
while scores of 1–4 indicate moderate burden and scores 
of $5 indicate substantial burden.12 Bivariate measures were 
created to measure the presence of select medical, psychiatric, 
and pain comorbidities. The list of comorbidities was chosen 
to complement the CCI, and included conditions shown in 
previous research1 to be prevalent among osteoarthritis 
patients (eg, hypertension, diabetes), conditions that may be 
associated with the osteoarthritis disease process or severity 
(eg, obesity, injuries) and conditions that may represent 
sequelae of osteoarthritis treatment (eg, peptic ulcer). The 
presence of these conditions may impact health care costs, 
so these measures were primarily created for use in the 
multivariate adjustment of health care costs. For all comor-
bidities, claims for laboratory and radiology services were 
not considered.
Medical utilization was measured over the 12-month 
post-index period and included medical and pharmacy ser-
vices for all osteoarthritis-related and non-osteoarthritis-
related services. Medical services included inpatient (facility 
and professional services associated with an inpatient admis-
sion), emergency department (defined based on place of 
service codes present in the database), and outpatient (all 
services not defined as inpatient, emergency department or 
pharmacy, which included services provided in physician 
offices, free-standing clinics, and hospital outpatient 
  departments). Osteoarthritis-related services were defined as 
claims with a diagnosis code for osteoarthritis or medications 
used in the management of osteoarthritis. Indication is not 
recorded on drug claims, and medications can have multiple 
uses, so osteoarthritis-related medication categorization is 
not exact. The final medication class list was based on review 
of previous research7 and clinician input, and included opi-
oids, tramadol, nonsteroidal anti-inflammatory drugs, topical 
analgesics, other analgesics not elsewhere classified, cycloox-
ygenase-2 (COX-2) inhibitors, proton pump inhibitors/H2 
blockers, intra-articular injections, muscle relaxants, anti-
convulsants, antidepressants, benzodiazepines (eg, estazo-
lam, flurazepam, temazepam) and nonbenzodiazepine 
sedative hypnotics (eg, ramelteon, zaleplon, zolpidem). 
Individual medications within each class were identified 
using Red Book™ drug class codes.
The primary study outcome was direct health care costs, 
which were determined by summing the paid amounts 
(including both the health plan and patient portions) on 
relevant claims. Costs for services provided under capitated 
arrangements were estimated using payment proxies 
  computed across all claims in the MarketScan databases. 
Payment proxies were used to assign a gross pay amount to 
capitated services. Proxy payments were specific to region, 
year, and current procedural terminology codes, and were 
generated using noncapitated data. The medical care com-
ponent of the US Consumer Price Index was used to adjust 
costs to December 2008 US dollars.
Bivariate descriptive analyses were conducted to char-
acterize the study population in terms of all demographic, 
comorbidity, medical utilization, and cost measures. Patient 
counts and percentages were reported for categorical vari-
ables, while mean and standard deviation were presented for 
continuous variables. Statistically significant differences 
between the osteoarthritis and nonosteoarthritis cohorts were 
tested using Chi-square tests for categorical variables and 
t-tests for continuous variables. A critical value of P , 0.05 
was set a priori as indicative of a significant difference 
between cohorts.
Multivariate analyses were conducted to estimate inpatient 
costs, outpatient costs, outpatient prescription drug costs, and 
total costs controlling for differences between cohorts that 
remained after matching. Emergency department costs and the 
individual components of outpatient costs (eg, primary care 
physician office visits, physical/occupational therapy) were not 
modeled separately because an initial descriptive review of cost 
data revealed these costs to be minimal.   However, these costs 
were included when modeling total costs. Model covariates 
included demographic variables from Table 1, as well as select 
comorbidities listed in Table 2. Comorbidities included in the 
model were selected using stepwise regression with backward 
selection; variables with a P value # 0.1 were used as model 
covariates. Generalized linear model regressions with log link 
and gamma variance functions were constructed for total and 
prescription drug costs. Two-part models, ie, logistic regressions 
of positive costs followed by generalized linear model regres-
sions of costs for patients with positive costs, were used for 
inpatient costs because many patients were not hospitalized. 
Park tests and Akaike’s information criterion were used to select 
the most appropriate variance functions in the models. The 
recycled prediction simulation was used to estimate and com-
pare marginal effects without removing the risk factors from 
the model; as a result, it was used to determine the impact of 
osteoarthritis diagnosis on health care costs, adjusting for 
patient characteristics. The 95% confidence intervals (CI) 
around the mean adjusted costs were determined using a boot-
strapping method with 500 iterations. The differences between 
the two full sample averages reflect the net effects of osteoar-
thritis status on health care costs.
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Table 2 Demographic characteristics
OA patients 
n = 258,237
Controls 
n = 258,237
P value
Age (mean, SD) 67.0 12.9 66.3 12.9 ,0.05
Age group (n, %) 0.999
  18–34 1563 0.6% 1563 0.6%
  35–44 7380 2.9% 7380 2.9%
  45–54 34,950 13.5% 34,950 13.5%
  55–64 81,007 31.4% 81,007 31.4%
  65–74 50,405 19.5% 50,405 19.5%
  75+ 82,932 32.1% 82,932 32.1%
gender (n, %) 0.999
  Male 92,345 35.8% 92,345 35.8%
  Female 165,892 64.2% 165,892 64.2%
geographic region (n, %) 0.999
  North Central 90,412 35.0% 90,412 35.0%
  Northeast 25,255 9.8% 25,255 9.8%
  South 95,361 36.9% 95,361 36.9%
  West 46,343 17.9% 46,343 17.9%
  Unknown 866 0.3% 866 0.3%
Health plan type (n, %) 0.999
  Comprehensive 103,499 40.1% 103,499 40.1%
  Exclusive provider organization 444 0.2% 444 0.2%
  Health maintenance organization 34,097 13.2% 34,097 13.2%
  Preferred provider organization 18,705 7.2% 18,705 7.2%
  Point of service 96,714 37.5% 96,714 37.5%
  Point of service with capitation 1118 0.4% 1118 0.4%
  Consumer driven health plan 1647 0.6% 1647 0.6%
  Unknown 2013 0.8% 2013 0.8%
Medicare coverage (n, %) 129,292 50.1% 129,292 50.1% 0.999
Abbreviations: OA, osteoarthritis; SD, standard deviation.
Table 1 Study sample selection
n Percentage
• Patients with at least one OA diagnosis from January 1, 2007 through December 31, 2007 1,010,071 100%
• Age 18 years or older at first OA diagnosis 1,007,532 99.7%
• Continuous enrollment and pharmacy benefits $12 months before first OA diagnosis 471,205 46.7%
• Continuous enrollment and pharmacy benefits $12 months after first OA diagnosis 470,416 46.6%
• Mental health benefits $12 months before first OA diagnosis 421,627 41.7%
• Mental health benefits $12 months after first OA diagnosis 420,889 41.7%
• Second OA diagnosis on/between 15 and 365 days pre- and post-index 259,886 25.7%
Total number of eligible patients for OA cohort 259,886 25.7%
Total number of matched OA patients 258,237 25.6%
Total number of non-OA controls 258,237
Notes: OA patients were directly matched 1:1 to control patients with no evidence of OA on the basis of age group, gender, geographic region, health plan type, and Medicare 
eligibility. OA patients for whom a match could not be located were dropped from the sample.
Abbreviation: OA, osteoarthritis.
Results
A total of 1,010,071 patients in the MarketScan Commercial 
and Medicare Supplemental Databases had an osteoarthritis 
claim in 2007 (Table 1). After excluding patients without a 
confirmatory osteoarthritis diagnosis (16%), patients without 
pre-index and post-index continuous enrollment (58%) and 
patients under the age of 18 years at index (,1%), the 
  remaining osteoarthritis patients (26%) were matched to 
controls without osteoarthritis. The final study sample 
included 258,237 osteoarthritis patients and an equivalent 
number of controls.
Patient demographic characteristics are presented in 
Table 2. Per study design, most patient characteristics (ie, age 
group, gender, geographic region, health plan type, and 
Medicare eligibility) were the same for both cohorts. The 
cohorts were predominantly female (64.2%), and about 83% 
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of patients were over the age of 55 years. Most patients 
resided in the North Central (35%) and South (36.9%) 
regions. The majority of patients were enrolled in a compre-
hensive (40.1%) or preferred provider organization (37.5%) 
health plan. Slightly over half (50.1%) of the patients were 
eligible for Medicare.
Osteoarthritis patients had a greater comorbid burden 
than demographically matched controls, as evidenced by the 
higher mean CCI score for osteoarthritis patients in the pre-
index (0.87 versus 0.61, P , 0.05, Table 3). Osteoarthritis 
patients also had significantly higher rates of all assessed 
individual comorbidities compared with controls. Common 
pre-index medical conditions in the osteoarthritis cohort 
included hypertension (44.8%), cardiovascular disease 
(29.0%), and diabetes (17.0%). These conditions also 
affected the controls, although at lower rates (32.5%, 20.4%, 
and 12.6%, respectively; all P , 0.05). Two to three times 
as many osteoarthritis patients as controls had claims in the 
12 months pre-index for pain conditions other than 
  osteoarthritis, including low back pain (17.7% versus 6.9%), 
neuropathic pain (4.3% versus 1.4%), inflammatory arthritis 
(4.5% versus 1.2%), and fibromyalgia (3.9% versus 1.2%), 
all of which were statistically significant (P , 0.05). 
  Depression was present pre-index among 6.4% of osteoar-
thritis patients compared with 3.4% of controls.
More osteoarthritis patients than controls utilized health 
care services in the 12 months post-index (Table 4). Nearly 
one-third (32.5%) of osteoarthritis patients incurred a hospi-
talization, compared with only 8.6% of controls (P , 0.05). 
More osteoarthritis patients than controls had a physician 
office visit with a primary care provider (88.7% versus 64.8%, 
P , 0.05) and a specialist (85.5% versus 48.6%, P , 0.05). 
Physical or occupational therapy was also utilized by more 
osteoarthritis patients than controls (43.6% versus 11.7%, 
P , 0.05). The majority of patients in both cohorts filled 
prescriptions during the post-index period, but there were 
more patients with at least one drug claim in the   osteoarthritis 
cohort than in the control cohort (96.3% versus 86.7%, 
P , 0.05). Pain-related medications were used by 86.9% of 
osteoarthritis patients compared with 52.6% of controls 
(P , 0.05).
Examination of the coefficients in the cost models 
(Table 5) revealed that a higher CCI score and presence of 
the majority of the pre-index comorbidities examined were 
Table 3 Comorbidities over the 12 month pre-index period
OA patients 
n = 258,237
Controls 
n = 258,237
CCIa (mean, SD) 0.87 1.34 0.61 1.19
Medical conditionsb (n, %)
  Hypertension 115,572 44.8% 83,826 32.5%
  Cardiovascular disease 74,930 29.0% 52,585 20.4%
  Diabetes 43,812 17.0% 32,450 12.6%
  Peptic ulcer or gastritis 9177 3.6% 4,723 1.8%
  Obesity 5049 2.0% 1539 0.6%
  Insomnia 4947 1.9% 2561 1.0%
  Kidney disease 4176 1.6% 2893 1.1%
  Liver disease 3707 1.4% 2511 1.0%
  Seizure or epilepsy 2729 1.1% 1984 0.8%
Psychiatric conditions (n, %)
  Depression 16,413 6.4% 8851 3.4%
  Alcohol use disorder 532 0.2% 289 0.1%
Pain conditionsb (n, %)
  Joint pain/arthralgia 96,410 37.3% 18,504 7.2%
  Injuries 76,984 29.8% 36,399 14.1%
  Low back pain 45,749 17.7% 17,891 6.9%
  Neuropathic pain 11,061 4.3% 3682 1.4%
  Inflammatory arthritisc 11,593 4.5% 3019 1.2%
  Fibromyalgia 10,183 3.9% 3025 1.2%
  Migraine 4757 1.8% 2778 1.1%
Notes: All comparisons were statistically significant with a P value , 0.05. aCharlson 
Comorbidity Index, Deyo adaptation, calculated over 12 months pre-index; bpresence 
of $one claim with a diagnosis code indicative of the condition in the 12 months pre-
index; cincludes rheumatoid arthritis, ankylosing spondylitis or psoriatic arthropathy.
Abbreviations: CCI, Charlson Comorbidity Index; OA, osteoarthritis; SD, standard   
deviation.
Table 4 Health care utilization over the 12-month post-index 
period
OA patients 
n = 258,237
Controls 
n = 258,237
Patients with services (n, %)
  Hospitalizations 84,010 32.5% 22,133 8.6%
  Emergency department 72,147 27.9% 50,133 19.4%
  Office visit, primary care 229,001 88.7% 167,442 64.8%
  Office visit, specialist 220,734 85.5% 125,457 48.6%
    Physical/occupational  
therapy
112,650 43.6% 30,105 11.7%
  All medications 248,594 96.3% 223,969 86.7%
  Pain-related medicationsa 224,427 86.9% 135,924 52.6%
Number of services (mean, SD)
  Hospitalizations 0.4 0.7 0.1 0.4
  Emergency department 0.5 1.2 0.3 1.0
  Office visit, primary care 5.5 5.3 2.4 3.2
  Office visit, specialist 5.3 5.4 1.9 3.5
    Physical/occupational  
therapy
5.0 9.7 1.0 4.6
  All medications 36.2 30.0 22.0 24.1
  Pain-related medicationsa 11.9 14.1 4.3 8.1
Notes: All comparisons were statistically significant with a P value , 0.05. aIncludes 
the  following  medications  that  may  be  used  to  treat  osteoarthritis  symptoms: 
opioids,  tramadol,  nonsteroidal  anti-inflammatory  drugs,  topical  analgesics,  other 
analgesics  not  elsewhere  classified,  cyclooxygenase-2  (COX-2)  inhibitors,  proton 
pump inhibitors/H2 blockers (may be prescribed for gastroprotection), intra-articular 
injections, muscle relaxants, anticonvulsants, antidepressants, benzodiazepines, and 
nonbenzodiazepine sedative hypnotics. These mediations may have other indications 
as  well.  Medications  not  resulting  in  an  outpatient  claim  (eg,  over-the-counter 
products) were not counted.
Abbreviations: OA, osteoarthritis; SD, standard deviation.
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associated with significantly increased costs. Mean total 
adjusted direct costs for osteoarthritis patients were 
US$18,435 (95% CI: US$18,318–US$18,560) in the 
12 months post index, ie, more than double the US$7494 
(95% CI: US$7425–US$7557) incurred by controls (Table 6). 
Inpatient costs were estimated at US$6668 (95% CI: 
US$6587–US$6744) for osteoarthritis patients and US$1756 
(95% CI: US$1717–US$1794) for controls. Mean outpatient 
costs were US$7840 (95% CI: US$7786–US$7902) for 
osteoarthritis patients and US$3675 (95% CI: US$3637–
US$3711) for the control group. Mean outpatient pharmacy 
costs were US$3213 (95% CI: US$3195–US$3233) for 
osteoarthritis patients and US$2245 (95% CI: US$2229–
US$2262) for controls.
Discussion
This study was conducted to compare the direct health care 
costs of osteoarthritis patients and a demographically 
matched control group to determine the cost burden associ-
ated with osteoarthritis. This study adds to the existing body 
of literature on the burden of osteoarthritis by assessing 
detailed health care utilization and costs in comparison with 
patients without the condition. Results showed that the direct 
health care costs of osteoarthritis patients were more than 
double the cost for similar patients without the condition. 
Higher inpatient costs among osteoarthritis patients were the 
primary driver of the cost difference. Additionally, the pres-
ence of pre-index comorbidities was associated with higher 
total costs.
In this retrospective analysis, osteoarthritis patients 
incurred annual total direct costs that were $10,941 higher, 
on average, than similar patients without osteoarthritis (in 
2008 US currency). This differential is larger than that 
presented in previous studies. Kotlarz et al found osteoarthritis 
increased annual costs by $4730 to $6212 (2007 US 
  currency), depending on gender.6 However, that study did 
not include all medical services, such as physical and 
occupational therapy, which may account for some of the 
  difference. Mapel et al noted that total costs for osteoarthritis 
patients were more than double those of controls,13 a finding 
that is consistent with the current study.
As in previous studies, inpatient admissions were a driver 
of costs among osteoarthritis patients. In this study, mean 
annual inpatient costs comprised about 36% of the total costs. 
Hospitalizations accounted for 37% of total costs for osteoar-
thritis patients included in the retrospective claims analysis 
Table 5 generalized linear model regression of all-cause total 
health care costs
Coefficienta Standard   
error
Key independent variable  
  Controls (reference)
  OA patients 0.900 0.005*
Age
gender 0.010 0.000*
  Male (reference)
  Female -0.053 0.005*
Urbanicity
  Rural or unknown (reference)
  Urban 0.003 0.006
Region
  South (reference)
  Northeast -0.020 0.009*
  North Central -0.022 0.006*
  West 0.044 0.008*
  Unknown -0.232 0.043*
Health plan type
  Comprehensive (reference)
  Exclusive provider organization 0.071 0.060
  Health maintenance organization -0.042 0.010*
  Point of service -0.018 0.011
  Preferred provider organization 0.031 0.007*
  Point of service with capitation -0.189 0.040*
  Consumer driven health plan 0.011 0.032
  Unknown 0.150 0.029*
Capitation status
  Not capitated (reference)
  Capitated 0.165 0.013*
Medicare -0.217 0.009*
Charlson Comorbidity Index 0.175 0.003*
Preperiod comorbidities
  Peptic ulcer/gastritis 0.161 0.015*
  Kidney disease 0.372 0.022*
  Liver disease 0.327 0.023*
  Hypertension 0.131 0.005*
  Obesity 0.183 0.022*
  Insomnia 0.112 0.021*
  Diabetes 0.097 0.008*
  Cardiovascular disease 0.259 0.006*
  Seizure or epilepsy 0.301 0.026*
  Depression 0.306 0.012*
  Alcohol use disorder 0.168 0.063*
  Neuropathic pain 0.166 0.015*
  Lower back pain 0.224 0.008*
  Migraine 0.281 0.021*
  Inflammatory arthritis 0.282 0.015*
  Injuries 0.122 0.006*
  Joint pain/arthralgia 0.138 0.006*
Constant 7.871 0.023*
Notes: *Significant with P , 0.05; aPositive coefficient indicates increase in cost, 
while negative coefficient indicates decrease in cost.
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Table 6 Regression-adjusted health care costs over the 12 month post-index period
  OA patients Controls
Mean 95% CI Mean 95% CI
Inpatient costs $6668 $6587 $6744 $1756 $1717 $1794
Outpatient costs $7840 $7786 $7902 $3675 $3637 $3711
Rx costs $3213 $3195 $3233 $2245 $2229 $2262
Total costs $18,435 $18,318 $18,560 $7494 $7425 $7557
Notes: Nonoverlapping confidence intervals indicate that the means are significantly different. All amounts are in US dollars.
Abbreviations: CI, confidence interval; OA, osteoarthritis.
by White et al.1 Similarly, Dunn and Pill reported 40% of the 
estimated total charges were from inpatient services.7 Mapel 
et al also found that osteoarthritis patients were nearly four 
times more likely to have a hospitalization than controls.13
This study found the health care utilization rates of 
osteoarthritis patients to be significantly greater than those 
of the control group across all service categories.   Furthermore, 
osteoarthritis patients had significantly more comorbidity 
compared with controls. Mapel et al determined that although 
osteoarthritis patients incurred more hospitalizations than 
controls, only about half the hospitalizations were for mus-
culoskeletal diagnoses.13 They found that outpatient neurol-
ogy, gastroenterology, and mental health-related outpatient 
utilization was nearly double that of controls without osteoar-
thritis, suggesting a considerable portion of the incremental 
burden of osteoarthritis is due not to the condition itself but 
to comorbidities.
The current study has some limitations which must be 
considered when interpreting the results. Absence of an 
osteoarthritis code in the claims histories of control patients 
does not necessarily mean some of these patients did not have 
osteoarthritis; patients could have untreated osteoarthritis 
symptoms or be under treatment without having the condition 
coded on their insurance claims. Comorbid conditions may 
have been underreported for similar reasons. Cost differences 
between cohorts could be due to unobserved factors not con-
trolled for through matching and multivariate regressions. 
Costs not resulting in a health plan claim (eg, over-the-counter 
medications, services covered entirely by Medicare and not 
submitted to the supplemental insurer) are not included in the 
database and, thus, could not be tallied for either osteoarthritis 
patients or controls. Study results were derived from 
  commercially insured patients and may not be generalizable 
to patients with Medicaid coverage or the uninsured. 
Additionally, as with most previous research,8 this study did 
not stratify the osteoarthritis sample by primary site of osteoar-
thritis (eg, knee versus wrist/hand) but rather summarized costs 
across all osteoarthritis patients. Thus, the study results are 
likely driven by the most prevalent types of osteoarthritis.
Conclusion
Results from this retrospective cohort study show that the 
health care resource utilization and cost burden associated 
with osteoarthritis is substantial. Overall, the commercially 
insured osteoarthritis patients in this study utilized more 
health care resources and cost significantly more than their 
matched controls. The primary cost drivers were comorbidi-
ties and inpatient costs.
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